Text Size

Resistance Training in Lung Cancer Patients on Chemotherapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Kristina Karvinen, East Carolina University
ClinicalTrials.gov Identifier:
NCT01130714
First received: January 6, 2010
Last updated: July 12, 2012
Last verified: July 2012
History of Changes
  Purpose

The purpose of this study is to examine the effectiveness of a resistance training program on reducing systemic inflammation and improving chemotherapy completion in lung cancer patients being treated with curative intent chemotherapy.


Condition Intervention
Inflammation
Lung Cancer
 Behavioral: Exercise

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by East Carolina University:

Primary Outcome Measures:
  • Systemic inflammation measured by c-reactive protein. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Chemotherapy completion [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 15
Study Start Date: January 2010
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Resistance training
Group assigned to complete resistance training during duration of chemotherapy.
 Behavioral: Exercise
Resistance training with resistance bands.
No Intervention: Control
Usual care.
 Behavioral: Exercise
Resistance training with resistance bands.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically diagnosed with lung cancer
  • Stage I, II, or III
  • Eligible for chemotherapy with curative intent
  • 21 years of age or older
  • Approval to participate in study by treating oncologist or family physician

Exclusion Criteria:

  • Unstable cardiac disease
  • Untreated bone or brain metastases
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01130714

Locations
United States, North Carolina
Leo Jenkins Cancer Center
Greenville, North Carolina, United States, 27834
Sponsors and Collaborators
East Carolina University
Investigators
Principal Investigator: Kristina H Karvinen, PhD East Carolina University
  More Information

No publications provided

Responsible Party: Kristina Karvinen, Assistant Professor, East Carolina University
ClinicalTrials.gov Identifier: NCT01130714     History of Changes
Other Study ID Numbers: UMCIRB 09-0725
Study First Received: January 6, 2010
Last Updated: July 12, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by East Carolina University:
inflammation
chemotherapy
lung cancer

Additional relevant MeSH terms:
Inflammation
Lung Neoplasms
Pathologic Processes
Respiratory Tract Neoplasms
Thoracic Neoplasms
 Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 16, 2013